Thursday, April 18, 2024 9:03:01 PM
Apollo will, when its planned acquisitions of Juventix and IPS are completed, operate the following businesses through its subsidiaries:
? Integrative Practice Solutions, LLC, or IPS, organized under the laws of the state of Florida, engaged in licensing of The Advanced Arthritis Relief Protocol™, sale and distribution of medical devices, clinical training, and medical integration services. IPS is established as a leader in the non-surgical outpatient treatment of Osteoarthritis. It has developed America’s largest osteoarthritis treatment network with 200 licensed clinics in 37 states. With its highly profitable, disruptive technology, IPS has carved out a niche for its services that leaves it open to very limited competition;
? MAXIMUS Men’s Health, or Maximus, organized under the laws of the state of Delaware, focusing on solutions for the modern health focused male. The combination of osteoarthritis treatments, with PRP, and new age biologic products has enabled us to create treatments for uniquely male problems such as sports injuries, hair loss, erectile dysfunction, and testosterone replacement under Maximus.
? Juventix Regenerative Medical, LLC, organized under the laws of the state of Florida, is our state-of-the-art Platelet-Rich Plasma, or PRP, offering. We have created a futuristic processing procedure that sets Juventix apart from all competition in the PRP world. This world-class PRP offering allows us to have a door opener which “starts the conversation” with doctors interested in regenerative medicine.
Our Acquired Companies are expected to have a large, seasoned base of established customers.
IPS features 221 current licensees of its patented Advanced Arthritis Relief Protocol™, in 35 states. Additionally, IPS sells unloading knee braces, medical supplies, and other consumables to a total of 468 past and current customers. Juventix supplies PRP blood processing kits, medical devices, and supplies to over 500 healthcare clinics in the Shared States, as well as limited distribution internally (primarily in the Middle East).
Juventix and our already owned subsidiary, Evolutionary Biologics sell biologic products to doctors in many fields. Both companies utilize 1099 sales representatives to call directly on the doctors who are potential customers.
Recent KOAN News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 04:51:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:03:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 10:28:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 08:22:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 11:03:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 10:05:51 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 03:08:06 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM